Cargando…

FIGO staging of endometrial cancer: 2023

INTRODUCTION: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berek, Jonathan S., Matias-Guiu, Xavier, Creutzberg, Carien, Fotopoulou, Christina, Gaffney, David, Kehoe, Sean, Lindemann, Kristina, Mutch, David, Concin, Nicole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2023
Materias:	FIGO Staging Update
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482588/ https://www.ncbi.nlm.nih.gov/pubmed/37593813 http://dx.doi.org/10.3802/jgo.2023.34.e85

Ejemplares similares

FIGO/ICM guidelines for preventing Rhesus disease: A call to action
por: Visser, Gerard H. A., et al.
Publicado: (2021)

FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication
por: Prat, Jaime
Publicado: (2015)

Clinical guidelines—the challenges and opportunities: What we have learned from the case of misoprostol for postpartum hemorrhage
por: Morris, Jessica L., et al.
Publicado: (2018)

FIGO staging for carcinoma of the vulva: 2021 revision
por: Olawaiye, Alexander B., et al.
Publicado: (2021)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists
por: Zheng, Wenxin
Publicado: (2023)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
por: Shakir, Rebecca, et al.
Publicado: (2022)

Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
por: Kasius, Jenneke C., et al.
Publicado: (2021)

P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
por: Parsons, Susan K., et al.
Publicado: (2022)

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
por: Santarsieri, Anna, et al.
Publicado: (2022)

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
por: Hutchings, Martin, et al.
Publicado: (2022)

42P Radiation induced pneumonitis in the era of the COVID-19 pandemic: Artificial intelligence for differential diagnosis
por: Ramella, S., et al.
Publicado: (2021)

44P Inter-reader variability of lung parenchymal observations on chest CT among COVID-19 RT-PCR negative lung cancer patients treated with chemo-radiation: Potential pitfalls of pulmonary findings in different readers with various experience levels
por: Jajodia, A., et al.
Publicado: (2021)

43P Incidentally discovered suspicious lung lesions in hospitalized patients during the COVID-19 pandemic in Georgia
por: Abuladze, M., et al.
Publicado: (2021)

Impact of the Covid-19 pandemic on a District General Hospital EBUS service
por: Wright, Matthew, et al.
Publicado: (2021)

P007: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
por: Dorokhina, Elena, et al.
Publicado: (2022)

T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
por: Diepstra, Arjan, et al.
Publicado: (2022)

P017: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma
por: Taszner, Michal, et al.
Publicado: (2022)

P014: Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
por: Sousa, Rita Costa E., et al.
Publicado: (2022)

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
por: Borchmann, Peter, et al.
Publicado: (2022)

P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
por: Viviani, Simonetta, et al.
Publicado: (2022)

P013: Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
por: Laura, Korin, et al.
Publicado: (2022)

P011: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose
por: Almeida, Cátia, et al.
Publicado: (2022)

P016: Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
por: Dragičević, Ida Hude, et al.
Publicado: (2022)

P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
por: Rusconi, Chiara, et al.
Publicado: (2022)

P012: Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience
por: Pierdomenico, Francesca, et al.
Publicado: (2022)

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
por: Visentin, Andrea, et al.
Publicado: (2022)

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022)

P003: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
por: Jain, Hasmukh, et al.
Publicado: (2022)

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2022)

P019: Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
por: Dorokhina, Elena, et al.
Publicado: (2022)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

P018: Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry
por: Biasoli, Irene, et al.
Publicado: (2022)

T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
por: Gallamini, Andrea, et al.
Publicado: (2022)

Increased proportion of patients diagnosed with lung cancer as a result of an acute hospital admission during the COVID-19 pandemic, and associated inequalities
por: Taylor, Rebecca
Publicado: (2023)

Impact of COVID 19 on EBUS services
por: Dugdale, Isobel, et al.
Publicado: (2023)

Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists
por: Soslow, Robert A., et al.
Publicado: (2019)

The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
por: Creutzberg, Carien L., et al.
Publicado: (2011)

FIGO staging in ovarian carcinoma and histological subtypes
por: Kehoe, Sean
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jkl9qbhmgfiuvm1hgfbn1knm1k